QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
🟢 Bridging academia and industry in pharmacoepidemiology What does it take to turn real-world data into decision-grade evidence?
Yesterday, Sara Hallum Søndergaard and Cathrine Tipsmark from our Danish office attended the Danish Society for Pharmacoepidemiology 2025 Annual Meeting, exploring how academic–industry partnerships can advance reliable RWE.
📊 Key takeaways:
➡️ Register-based RCTs enabling cost-efficient, large-scale trials
➡️ Case-crossover designs for cumulative drug effects
➡️ Growing trust in RWE among European payers
It was energising to connect with both industry and academic colleagues on how registry-based research can support […]
Sometimes team building means working on your backhand
🎾Last week, we traded data models for tennis rackets and hit the courts with professional coaches for a fun afternoon of tennis.
Team Quantify includes both seasoned players and enthusiastic beginners, but the real goal was time together outside our usual element.
Unlock Global Insights with Nordic RWE
October is a busy month for Quantify Research!
We’re heading across Europe and the US to share how Nordic real-world evidence (RWE) drives global impact for Market Access, HEOR, and beyond.
Nordic data is globally recognized as a gold standard, thanks to:
✅ 27M+ population coverage across Sweden, Denmark, Norway & Finland
✅ Rich, linked datasets spanning hospitals, pharmacies, cancer registries & more
✅ Exceptional support for rare disease research
✅ Robust HEOR insights connecting outcomes […]
🧠Quantifying burden across borders: Japanese Encephalitis in APAC
At today’s ISPOR Real-World Evidence Summit 2025 , Puneet Kaushik presented new insights into the economic burden of Japanese Encephalitis(JE) across Asia-Pacific.
🔍 Despite vaccines and treatments, JE continues to strain health systems through:
• High inpatient and ICU demands
• Significant productivity losses—up to 860 workdays per case
• Wide cost variability: from $106 to $1,644 per case across countries
This systematic review drew from real-world data in China, Bangladesh, Indonesia, the Philippines and […]
